Proposed Board Changes

Fulcrum Pharma PLC
10 January 2008



Final                                                        10th January 2008

                               FULCRUM PHARMA PLC
                                ('the Company')

   Succession planning for growth and integration of European businesses for
                             improved profitability


Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services
company, announces that Jon Court, Chief Executive Officer, has indicated his
desire to step down as Chief Executive. Fulcrum has grown from a small UK
business of under 10 people at the time of its listing on AIM in 2000 to one
with offices on 3 continents, with over 150 employees and revenues of £11.5M. Dr
Court considers that the Company's long term prospects will be better served by
the appointment of a Chief Executive with the experience of managing a large,
multinational business. The Board has accepted Dr Court's wishes and the process
of searching for a new Chief Executive has commenced.

In addition to these succession plans, the Board is preparing the Company for
its next growth phase. Dr Angus Bell, non executive director, has been appointed
to lead the integration of its businesses in Europe to improve profitability and
enable further expansion through organic growth and M&A activity.

Dr Court will remain with the company in a business development and client
project role focussing on long term client relationships.

Jon Court, Chief Executive of Fulcrum Pharma, said: 'Fulcrum has changed
substantially from when I co-founded the business in 2000. I now feel that the
time has come for Fulcrum to appoint a new chief executive with the requisite
skills and background to take the business further forward. I remain, however,
fully committed to Fulcrum and look forward to working closely with Dr Bell and
the new chief executive once he or she is appointed'



For further information, please contact:

Fulcrum Pharma PLC
Jon Court, Chief Executive                     Tel: [phone]

Seymour Pierce
Jonathan Wright                                Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones. Fulcrum Pharma offers immediate access to a highly credible,
integrated development team that provides strategic and operational leadership
required to ensure that new drugs move smoothly from discovery research to
product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having
successfully floated in March 2000.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
        BLMPTMMMMBRP